海南医科大学学报

目的:探讨艾迪注射液联合肝动脉化疗栓塞术(TACE)对原发性肝癌患者的临床疗效及对血清甲胎蛋白(AFP)、碱性成纤维细胞生长因子(bFGF)、血管内皮生长因子(VEGF)水平、炎症细胞因子、细胞免疫功能以及生活质量的影响。方法:选取2017年6月～2019年6月上海杨思医院和复旦大学附属中山医院的原发性肝癌患者116例作为研究对象,随机分为TACE组和TACE+艾迪组,每组58例。TACE组给予TACE治疗,TACE+艾迪组在TACE组基础上给予艾迪注射液治疗。观察两组临床疗效、血清肿瘤标志物指标、bFGF、VEGF、TGF-β1水平、氧化应激指标、炎症细胞因子、细胞免疫功能以及生活质量的变化。结果:TACE+艾迪组总有效率显著高于TACE组,差异具有统计学意义(P<0.05)。治疗后两组AFP、糖链抗原(CA)242、CA724、bFGF、VEGF、转化生长因子-β1(TGF-β1)、丙二醛(MDA)、白细胞介素(IL)-6、IL-10、肿瘤坏死因子(TNF)-a、循环免疫复合物(CIC)、CD8⁺水平低于治疗前;总抗氧化能力(TAOC)、测超氧化物歧化酶(SOD)、IL-12、CD3⁺、CD4⁺、CD4⁺/CD8⁺水平、生活质量QOL评分高于治疗前。且TACE+艾迪组血清肿瘤标志物指标、bFGF、VEGF、TGF-β1水平、氧化应激指标、炎症细胞因子、细胞免疫功能以及生活质量改善情况显著优于TACE组,差异具有统计学意义(P<0.05)。TACE+艾迪组不良反应发生率低于TACE组,差异无统计学意义(P>0.05)。结论:艾迪注射液联合肝动脉化疗栓塞术对原发性肝癌患者临床疗效显著,降低血清肿瘤标志物水平,减少毒副反应,调节氧化应激水平,降低炎症反应程度,并降低血清bFGF、VEGF、TGF-β1水平,改善患者生活质量,具有较高的有效率和安全性,值得临床进一步推广。

Objective: To investigate the clinical effect of Aidi injection combined with TACE on patients with primary liver cancer and its influence on serum AFP, bFGF, VEGF, inflammatory cytokines, immune function and quality of life. Methods: From June 2017 to June 2019, 116 patients with primary liver cancer from Shanghai Yangsi hospital and Zhongshan Hospital Affiliated to Fudan University were selected as the study objects. They were randomly divided into TACE group and TACE + Aidi group with 58 cases in each group. The TACE group was treated with TACE. The clinical efficacy, serum tumor markers, bFGF, VEGF, TGF-beta 1, oxidative stress, inflammatory cytokines, cellular immune function and quality of life were observed. Results: The total effective rate was 89.66% in the case group, which was significantly higher than 74.14% in the TACE group, the difference was statistically significant(P<0.05). After treatment, the levels of alpha-fetoprotein(AFP), carbohydrate chain antigen(CA) 242, CA724, basic fibroblast growth factor(bFGF), vascular endothelial growth factor(VEGF), transforming growth factor-beta 1(TGF-beta), malondialdehyde(MDA), interleukin(IL)-6, IL-10, tumor necrosis factor(TNF)-a, circulating immune complex(CIC), CD8⁺ in the two groups were lower than those before treatment; total antioxidant capacity(TAOC), measurement The levels of superoxide dismutase(SOD), IL-12, CD3⁺, CD4⁺, CD4⁺/CD8⁺ and QOL scores of quality of life were higher than those before treatment. The serum tumor markers, bFGF, VEGF, TGF-beta 1, oxidative stress, inflammatory cytokines, cellular immune function and quality of life in theTACE + Aidi group were significantly better than those in the TACE group. The difference was statistically significant(P<0.05). The incidence of adverse reactions in theTACE + Aidi group was 6.89%, which was lower than 13.78% in the TACE group, There was no significant difference(P>0.05). Conclusions:Addie injection combined with transcatheter arterial chemoembolization is effective in treating primary liver cancer, reducing serum tumor markers, reducing toxic and side effects, regulating oxidative stress, reducing inflammatory reaction, reducing serum bFGF, VEGF and TGF-beta 1 levels, improving the quality of life of patients, and has high efficiency and safety, which is worthy of further promotion in clinic.